ATRA (Atara Biotherapeutics) Tariff Resilience Score: 8/10 (As of Jul. 01, 2026)


ATRA Atara Biotherapeutics Inc ATRA
31 GF Score
Price $11.45
GF Value $1.56
Valuation Significantly Overvalued
! 7 Warning Signs
View Full Analysis

What is Atara Biotherapeutics Tariff Resilience Score?

Atara Biotherapeutics ATRA +2.78% 31 Tariff Resilience Score is 8 as of Jul. 01, 2026. GuruFocus rates ATRA with a GF Score™ of 31/100 and a GF Value™ of $1.56 (Significantly Overvalued). The stock has 7 warning signs investors should review. Among 1,375 Biotechnology companies, Atara Biotherapeutics ranks better than 98.69% on this metric.

Atara Biotherapeutics has the Tariff Resilience Score of 8, which implies that the company might have Highly Resilient.

Atara Biotherapeutics has Atara Biotherapeutics primarily operates in the biotech sector, which is less affected by tariffs. Its focus on R&D and limited manufacturing exposure to international trade reduces vulnerability. However, any changes in trade policies affecting raw materials could pose risks.

Tariff Resilience Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more.

The company's exposure to international trade tariffs based on these criteria:

1. Global supply chain dependencies
2. Manufacturing locations versus sales markets
3. Import/export balance and percentage of revenue
4. Historical impact from previous tariff changes
5. Available mitigation strategies (alternative suppliers, pricing power)
6. Industry-specific tariff exemptions or vulnerabilities

Based on the research, GuruFocus believes Atara Biotherapeutics might have Highly Resilient.

Atara Biotherapeutics  (NAS:ATRA) Tariff Resilience Score Explanation

The Tariff Resilience Score ranges from 0 to 10, with 10 as the most resilient. GuruFocus divided Moat Score into following 3 categories:

Tariff Resilience Score Resilience Level
7 - 10Highly Resilient
4 - 6Average Resilient
0 - 3Highly Vulnerable

Atara Biotherapeutics Tariff Resilience Score Related Terms

ATRA vs ANIX, BMEA, PMN: Tariff Resilience Score Comparison

For the Biotechnology subindustry, Atara Biotherapeutics's Tariff Resilience Score, along with its competitors' market caps and Tariff Resilience Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Atara Biotherapeutics Tariff Resilience Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Atara Biotherapeutics's Tariff Resilience Score distribution charts can be found below:

* The bar in red indicates where Atara Biotherapeutics's Tariff Resilience Score falls into.


ATRA
31GF Score
Atara Biotherapeutics Inc ATRA
Tariff Resilience Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a Tariff Resilience Score of 8 mean?
Atara Biotherapeutics (ATRA) has a Tariff Resilience Score of 8 as of Jul. 01, 2026. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. According to the industry distribution chart, Atara Biotherapeutics ranks #18 out of 1375 companies in the Biotechnology industry, placing it in the top 1.3%.
Is Atara Biotherapeutics' Tariff Resilience Score too high?
Atara Biotherapeutics' current Tariff Resilience Score is 8. The Biotechnology industry median Tariff Resilience Score is 4.00. Atara Biotherapeutics' value of 8 is 100% above this industry median. Based on the distribution chart, Atara Biotherapeutics ranks #18 out of 1375 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Atara Biotherapeutics has a GF Score™ of 31/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Atara Biotherapeutics' Tariff Resilience Score compare to ANIX and BMEA?
According to the Biotechnology industry distribution chart, Atara Biotherapeutics ranks #18 out of 1375 companies for Tariff Resilience Score. This places Atara Biotherapeutics in the top 1% of its industry — outperforming the majority of peers. The industry median Tariff Resilience Score is 4.00. Atara Biotherapeutics' value of 8 is 100% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Tariff Resilience Score for a Biotechnology company?
The median Tariff Resilience Score among Biotechnology companies is 4.00, based on 1,375 companies in the industry. Companies in the top quartile (top 25%) have a Tariff Resilience Score significantly above this median, while those in the bottom quartile fall well below. However, Tariff Resilience Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Atara Biotherapeutics's current Tariff Resilience Score of 8 is 100% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Tariff Resilience Score mean?
A high Tariff Resilience Score can signal that a stock is expensive relative to its fundamentals. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. For the Biotechnology industry, the median Tariff Resilience Score is 4.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Atara Biotherapeutics's current Tariff Resilience Score is 8. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Atara Biotherapeutics stock overvalued right now?
Based on GuruFocus' analysis, Atara Biotherapeutics (ATRA) is currently considered Significantly Overvalued. The stock's GF Value™ is $1.56, compared to a current price of $11.45 — trading 634% above its estimated fair value. The current Tariff Resilience Score is 8 and 100% above the Biotechnology industry median of 4.00. Atara Biotherapeutics' overall GF Score™ is 31/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Tariff Resilience Score calculated?
Tariff Resilience Score is calculated from a company's financial statements. For Atara Biotherapeutics (ATRA), the current Tariff Resilience Score is 8 as of Jul. 01, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Atara Biotherapeutics (ATRA) Overvalued in 2026?

Based on GuruFocus' analysis, Atara Biotherapeutics stock appears to be overvalued. The current stock price of $11.45 is trading 634% above its estimated GF Value™ of $1.56. GuruFocus considers Atara Biotherapeutics to be Significantly Overvalued.

Key valuation signals for ATRA:

  • Tariff Resilience Score: 8
  • GF Value™: $1.56 vs. price of $11.45 (634% above fair value)
  • GF Score™: 31/100 with 7 warning signs
  • Industry Position: 100% above the Biotechnology median (#18 of 1375)

No single metric tells the full story. See the ATRA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Atara Biotherapeutics Business Description

Other Exchanges 0HIY:UKAT20:Germany
Address 1280 Rancho Conejo Boulevard, Suite 200, Thousand Oaks, CA, USA, 91320
Atara Biotherapeutics Inc operates in the United States healthcare sector. It focuses on developing transformative therapies for patients with serious diseases, including solid tumors, hematologic cancers, and autoimmune diseases. It operates and manages business as one operating and reportable segment which is the business of developing therapeutics. The company's product candidates comprise Tab-cel, ATA3431, and ATA3219.
31GF Score

Get the complete analysis for ATRA

Tariff Resilience Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$11.45
Price
$1.56
GF Value